重新审视过氧化作为固体瘤细胞的放射敏感剂
F Geirnaert1, L Kerkhove1, A Rifi1
1Department of Radiotherapy, UZ Brussel, Vrije Universiteit Brussel, 1090 Brussels, Belgium.
概括
科奇氧化物辐射用于不可切除的癌症 (KORTUC),氧化物和氨酸的组合,有效地克服瘤缺氧诱导的放射电阻. 这种新疗法抑制了氧气消耗,导致瘤再氧化和增强的辐射敏感性.
科学领域:
- 在瘤学瘤学.
- 辐射瘤学 辐射瘤学
- 癌症生物学 癌症生物学
背景情况:
- 瘤缺氧是癌症治疗中放射电阻的主要驱动因素.
- 过氧化 (H2O2) 作为放射敏感剂,但由于稳定性和毒性而面临临临床挑战.
- 氨酸 (SH) 用于改善H2O2的输送和稳定性,用于内注射.
研究的目的:
- 在缺氧瘤模型中研究科奇氧化物辐射对不可切除癌症 (KORTUC) 的放射调节效应和潜在机制.
- 评估KORTUC在克服缺氧诱导的放射电阻方面的有效性.
- 评估KORTUC作为组合治疗的安全性和治疗潜力.
主要方法:
- 在体外研究中,CT26和4T1细胞在低氧条件下暴露于H2O2,SH和KORTUC.
- 毒性通过MTT测定和活细胞分析进行评估;放射敏感性特性通过殖民地形成测定和球形模型进行评估.
- 研究的机制包括反应性氧物种 (ROS) 水平,DNA损伤,亡,铁亡,氧消耗率 (OCR),线粒体复合体活性和口内氧气水平.
- 在CT26携带的小鼠中进行了体内验证.
主要成果:
- 与单独使用的H2O2相比,KORTUC的细胞毒性降低.
- 科尔图克 (KORTUC) 证明了低氧瘤细胞的剂量依赖性放射敏感化,增强比为CT26的3.1和4T1的2.7.
- KORTUC治疗导致OCR降低,线粒体复合物I和II的抑制,以及线粒体ROS的升高.
- 在2D低氧模型中,KORTUC的内注射增加了氧气水平,并在小鼠中延迟了14天的CT26瘤生长.
结论:
- 在KORTUC中的氨酸 (SH) 有效地减轻过氧化 (H2O2) 的细胞毒性.
- KORTUC通过通过线粒体复合体I和II阻塞抑制氧气消耗,从而克服缺氧诱导的放射电阻,促进瘤再氧化.
- 了解这些机制对于开发涉及KORTUC的先进癌症组合疗法至关重要.
相关概念视频
01:24Peroxisomes
10.5K
Peroxisomes are specialized organelles present in fungi, plant, and animal cells. It can vary in number, size, morphology, and activity depending on the type of tissue and the nutritional state of the cell. For example, cells with active lipid metabolism, such as adipocytes, neurons, and hepatocytes, have more peroxisomes than other cells in the body. Besides their primary role in breaking down complex organic molecules, peroxisomes can also synthesize specific macromolecules and participate in...
10.5K
02:49Cancer Therapies
7.5K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.5K